[A14-44] Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Last updated 02.03.2015
Project no.:
A14-44
Commission:
Commission awarded on 24.11.2014 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-41 | Ledipasvir/sofosbuvir (hepatitis C) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-14 | Ledipasvir/sofosbuvir (Addendum to Commission A14-44) | Commission completed |
| A20-63 | Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2015-05-21 A G-BA decision was published.